Objective:
Lenvatinib is an oral multitarget tyrosine kinase inhibitor
(mTKI) and is recommended for patients with advanced hepatocellular carcinoma (HCC) with
Child-Pugh A liver function, who are not amenable to surgical resection, locoregional
treatment, or transcatheter arterial chemoembolization. Hepatogastric fistula is a rare
complication with a poor prognosis in patients with HCC. Previous reports on fistula
formation during mTKI therapy for HCC were all associated with sorafenib. Here, we report
the first case of recurrent hepatogastric fistula during lenvatinib therapy for advanced
HCC managed using an over-the-scope clip (OTSC).
Patient:
We present the case of a 73-year-old man with alcoholic liver
cirrhosis who was treated for multiple HCC for 7 years. HCC was treated using repetitive
transcatheter arterial chemoembolization, radiofrequency ablation, and sorafenib. Owing to
disease progression, lenvatinib treatment was started. During lenvatinib treatment,
recurrent hepatogastric fistulas developed. An OTSC was useful for fistula closure and
prevention of recurrence.
Results:
The major cause of fistula formation is considered to be the direct
invasion of HCC; however, HCC treatment might also be a contributing factor in our case.
In addition, OTSC was useful for fistula closure.
Conclusion:
Clinicians should be aware of the fatal complications during HCC
treatment.